券商推荐评级 - Intuitive Surgical, Inc.目前的平均券商推荐评级(ABR)为1.61，根据23家券商公司实际推荐（买入、持有、卖出等）计算得出[2] - 23家券商推荐中，有15家为强烈买入，2家为买入，强烈买入和买入分别占所有推荐的65.2%和8.7%[3] 投资决策 - 投资者通常依赖分析师推荐来决定是否买入、卖出或持有股票，媒体报道关于这些券商分析师的评级变化通常会影响股票价格[1] - 券商推荐趋势显示应购买Intuitive Surgical, Inc.，但仅凭此信息做出投资决策可能不明智，研究表明券商推荐在引导投资者选择具有最佳价格增长潜力的股票方面成功有限甚至没有[4]

公司股价表现 - Intuitive Surgical, Inc. (ISRG) 是 Zacks.com 访问者最近关注的股票之一[1] - 过去一个月，该公司的股价回报率为+3.8%，而 Zacks S&P 500 综合指数为+5%[2] - Zacks Medical - Instruments 行业在此期间获得了3.3%的增长[2] 盈利预期 - Intuitive Surgical, Inc. 预计本季度每股盈利为1.39美元，同比增长+13%[5] - 本财年的一致盈利预期为6.18美元，同比增长+8.2%[6] - 下一财年的一致盈利预期为7.27美元，同比增长+17.7%[7] 公司财务表现 - 公司上一季度营收为19.3亿美元，同比增长+16.5%，每股盈利为1.60美元[10] - 公司在过去四个季度中均超过了一致盈利预期[12] 公司评级和股价 - 公司的 Zacks Rank 为 4 (卖出)，显示了近期股价表现[8] - 公司的 Zacks Value Style Score 为 D，表明其股价较同行公司高出[16] - 公司的 Zacks Rank 4 暗示了可能在短期内表现不佳[17]

财务表现 - Intuitive Surgical公司第四季度调整后每股收益为1.60美元，超过Zacks Consensus Estimate的1.47美元，同比增长30%[3] - 公司报告的营收为19.3亿美元，同比增长17%[5] - Instruments & Accessories部门的营收达到11.4亿美元，同比增长21.6%，这主要归因于da Vinci手术的21%手术量增长[7]

Intuitive Surgical, Inc. (ISRG) closed the most recent trading day at $380.23, moving +0.69% from the previous trading session. This change outpaced the S&P 500's 0.13% gain on the day. Elsewhere, the Dow gained 0.13%, while the tech-heavy Nasdaq lost 0.32%. The the stock of company has risen by 1.68% in the past month, lagging the Medical sector's gain of 3.87% and the S&P 500's gain of 2.99%. The investment community will be paying close attention to the earnings performance of Intuitive Surgical, Inc. in ...

Intuitive Surgical (NASDAQ:ISRG) - 2023年第四季度，ISRG的系统收入增长了6%，达到约4.8亿美元[4] - 预计2024年全球达芬奇手术的数量将增长13%至16%[5] Sarcos Technology and Robotics (NASDAQ:STRC) - 预计2024年公司将以约3900万美元的现金、现金等价物和可市场化证券结束年度[7] - STRC与美国空军签署了一份价值1380万美元的四年发展合同[9] - Jeffries的分析师预计STRC有109.85%的上涨空间[10] Smith & Nephew (NYSE:SNN) - 公司预计到2025年将实现超过2亿美元的年度节省[14] - 机器人手术市场仍处于起步阶段，SNN在其特定用例中处于有利位置[15]

医疗保健行业投资 - 医疗保健行业一直是投资者积累财富的坚实领域[1] - 投资医疗股票需要注意监管变化、支付者变化、法律挑战和专利在这一领域的作用[1] Intuitive Surgical - Intuitive Surgical是外科机器人领域的领导者，通过销售其标志性的da Vinci外科机器人系统赚取巨额利润[3] - Intuitive Surgical不仅从机器人套件的仪器和配件中获得利润，还从为客户提供的各种服务中获得可观收入[4] - Intuitive Surgical从每个使用其da Vinci系统进行的外科手术中获得来自仪器和配件的收入，以及来自系统销售或租赁的服务合同的年度费用[5] Vertex Pharmaceuticals - Vertex Pharmaceuticals是囊性纤维化疗法领域的领导者，其药物组合在2023年实现了巨额利润[9] - Vertex Pharmaceuticals的畅销药Trikafta在2023年占据了公司总收入的90%，销售额持续增长[10] - Vertex Pharmaceuticals估计在北美、欧洲和澳大利亚有高达92,000名患者可以从其囊性纤维化疗法中受益[11] - Vertex Pharmaceuticals正在研发一种新的三联疗法，预计今年将寻求批准，该疗法比Trikafta更有效[13] - Vertex Pharmaceuticals还与Moderna合作开发基于mRNA的囊性纤维化疗法，针对无法接受CFTR调节剂的患者[14]

Robotics has the potential to transform various industries, particularly manufacturing and healthcare, by creating new opportunities for automation and efficiency. The sector could very well be on its way to entering a hyper-growth stage as technological advances continue to make these technologies not only possible but efficient. Investors looking to balance long-term returns with exposure to cutting-edge technologies should look no further than these three robotics stocks in February 2024. Intuitive Surgi ...

In the bustling realm of forward-looking investments, robotics stocks stand out for their tremendous potential and relevance. These dynamic assets offer around-the-clock productivity, virtually uninterrupted by the mundane constraints of human labor. With robots pausing for maintenance, their deployment can meaningfully boost operational efficiency. This edge is critical at a time when experts forecast the robotics sector to expand at an impressive compound annual growth rate (CAGR) of 10.5% from 2023 to 20 ...

Intuitive Surgical, Inc. (ISRG) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this company have returned +6.7% over the past month versus the Zacks S&P 500 composite's +5.8% change. The Zacks Medical - Instruments industry, to which Intuitive Surgical, Inc. belongs, has gained 4.3% over this period. Now the key question is: Where could the stock be hea ...

As you build your portfolio over time, it's good to diversify your investments into a wide range of stocks and sectors. Be sure they align with your overall goals and risk tolerance -- and that they can help you work toward the returns you desire. The healthcare industry is full of compelling businesses that are often at the forefront of medicine, developing cutting-edge treatments, medical devices, and other products that are changing the face of healthcare while serving a broad and growing market. While h ...